Tetrahydrobiopterin

Phase 2Small molecule

OOrphanetics Pharma Entwicklungs GmbH

Tetrahydrobiopterin is one of 96 small molecule programs targeting Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

PhenylketonuriaActive, not recruiting

EnteritisActive, not recruiting

Lung DiseasePhase 1

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

PhenylketonuriaPhase 1

Active, not recruiting

EnteritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

26 2

Tetrahydrobiopterin

OOrphanetics Pharma Entwicklungs GmbH

Phase 2

2 3

Flovent

GSK

Preclinical

6 4

Spiriva

Boehringer Ingelheim

Preclinical

15 5

Aclidinium Bromide

AstraZeneca

Preclinical

21 6

Formoterol Fumarate

AstraZeneca

Preclinical

11 7

Duragesic

CCephalon

Preclinical

2 8

Coumadin

AAbbott

Preclinical

1 9

Zoloft

VViatris Specialty LLC

Preclinical

1 10

Narcan

SScienture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

Completed·—·N/A·NCT01398943·60 enrolled

Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease

Completed·—·Phase 2·NCT02774226·15 enrolled

Alzheimer's Disease1 trial

Endothelial Facilitation in Alzheimer's Disease

Completed·UUniversity of Massachusetts, Worcester·Phase 2·NCT01439555·11 enrolled

Injury1 trial

A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury

Unknown status·WWest China Second University Hospital·Phase 1·NCT05114226·45 enrolled

Renal Failure1 trial

Exercise Intolerance in Renal Failure

Completed·EEmory University·Phase 2·NCT01356966·74 enrolled

Enteritis1 trial

A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis

Unknown status·WWest China Second University Hospital·Phase 2·NCT05138887·366 enrolled

4 more indications

Blood Pressure1 trial

Effects of Tetrahydrobiopterin on Blood Pressure

Completed·EEmory University·Phase 1·NCT00208780·24 enrolled

Lung Disease1 trial

O2 Transport and Utilization in Health and Lung Disease

Withdrawn·—·Phase 1·NCT04014712

Treatment1 trial

Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety

Terminated·OOrphanetics Pharma Entwicklungs GmbH·Phase 2/3·NCT00432822·50 enrolled

Phenylketonuria1 trial

Response to Phenylketonuria to Tetrahydrobiopterin (BH4)

Terminated·TThe University of Texas Medical Branch, Galveston·Phase 1·NCT00244218·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Tetrahydrobiopterin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tetrahydrobiopterin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tetrahydrobiopterin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Orphanetics Pharma Entwicklungs GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOrphanetics Pharma Entwicklungs GmbH

Tetrahydrobiopterin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Obstructive Pulmonary Disease2 trials

Alzheimer's Disease1 trial

Injury1 trial

Renal Failure1 trial

Enteritis1 trial

Blood Pressure1 trial

Lung Disease1 trial

Treatment1 trial

Phenylketonuria1 trial

References

Drug Info

Quick Facts

Related News